Novavax Announces Management Promotions
June 19 2014 - 4:26PM
GAITHERSBURG, Md., June 19, 2014 (GLOBE NEWSWIRE)
-- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical
company focused on the discovery, development, and
commercialization of recombinant nanoparticle vaccines and
adjuvants, announced today a number of promotions within its
management team.
John A. Herrmann III, J.D. has been named Senior
Vice President, General Counsel and Corporate Secretary. Mr.
Herrmann joined Novavax in March 2010 and is responsible for
managing all of Novavax' legal affairs, including its patent
portfolio, transactional and contractual matters, public securities
filings, and attending to all the duties of Corporate Secretary.
Mr. Herrmann also works with the company's senior management team
to define and develop corporate policies and procedures. Prior to
joining Novavax, Mr. Herrmann served as General Counsel at Ore
Pharmaceuticals and Deputy General Counsel at Gene Logic before it
became Ore Pharmaceuticals. Prior to joining Gene Logic, Mr.
Herrmann served as Senior Counsel for Celera Genomics and prior to
that as Senior Corporate Counsel at Baxter Healthcare in its Renal
Division. Mr. Herrmann received his B.A. in Political Science and
History from Brown University and his J.D. from the University of
Illinois.
Denise Courbron, M.S., PMP has been named Vice
President, Global Program Management to lead Novavax' program
management efforts covering all vaccine development programs. Ms.
Courbron joined Novavax in June 2010 as Executive Director, Global
Program Management and was instrumental in Novavax' being awarded
its $179 million influenza development contract with HHS BARDA in
February 2011. Prior to joining Novavax, Ms. Courbron held
positions of increasing responsibility in a number of companies in
the vaccines industry, including PharmAthene, Intercell USA, Iomai
Corporation, PPD, Baxter BioScience, GloboMax (ICON), and North
American Vaccine. Ms. Courbron received a B.A. in Political Science
and Spanish from Western Maryland College (McDaniel) and an M.S. in
Biotechnology Management from the University of Maryland University
College. Ms. Courbron is a certified Project Management
Professional (PMPTM).
"I am very pleased to announce the promotions of
John and Denise. Their contributions over the last number of years
have been critical to the success of the company. John has been
irreplaceable assisting the management team and the board to
navigate the regulatory, compliance, and corporate governance
requirements of a public company. Denise's long history of
experience with government contracts and project management has
been integral to the successful execution of our contract with HHS
BARDA. I look forward to their continued involvement in the success
of the company," said Stanley C. Erck, President and CEO.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biopharmaceutical company creating novel vaccines and vaccine
adjuvants to address a broad range of infectious diseases
worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine
candidates to efficiently and effectively respond to both known and
newly emergent diseases. Additional information about Novavax is
available on the company's website, novavax.com.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#1797251
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024